States that decriminalized medical cannabis were associated with fewer health-related workplace absences, according to a study published online in June 2026. Recreational legalization was not associated with a statistically significant change in the same outcome.
This is a population-level policy study using repeated survey data. It estimates changes around state laws, not the health effects of a particular cannabis product, dose or treatment plan.
What the Study Found
The peer-reviewed study in the Journal of Workplace Behavioral Health reported that medical cannabis decriminalization was associated with about a 6.9% reduction in the probability that employed adults were absent from work for health-related reasons. The authors did not find a significant overall effect after recreational cannabis legalization.
The result is about the likelihood of an absence in the survey period, not a 6.9% improvement in health, productivity or hours worked. It also does not mean every state, occupation or worker experienced the same change.
How the Researchers Reached the Estimate
The researchers analyzed monthly Current Population Survey data from January 1990 through March 2025. The U.S. Census Bureau describes the CPS as the country's primary source of labor-force statistics. Its repeated monthly design allows researchers to compare employment outcomes across states and time.
The study used a flexible difference-in-differences model. In plain language, the approach compared changes in states adopting a cannabis policy with changes in states that had not adopted it at the same time. That can reduce some common before-and-after biases, especially when laws take effect in different years.
The model still relies on assumptions. States do not pass cannabis laws randomly. Changes in paid leave, health coverage, economic conditions, workplace culture and other health policies may happen near the same time. Statistical controls can address measured differences, but not every unmeasured influence.
Medical and Recreational Laws Were Not Interchangeable
The contrast between medical decriminalization and recreational legalization is one of the most useful parts of the paper. If any relaxation of cannabis penalties automatically reduced absence, both policy categories might be expected to move similarly. They did not.
One possible explanation is that medical laws change access for people managing symptoms that can interfere with work. Another is that the laws are markers for broader health or employment-policy changes. The study cannot determine which pathway produced the association, and it does not identify whether workers actually used cannabis.
This is why findings from policy studies should not be used as clinical advice. CannaWize's review of cannabinoids for chronic pain examines randomized treatment evidence, while this workplace study examines state-level policy exposure. They answer different questions.
What Employers Should and Should Not Conclude
The paper does not show that cannabis use improves job performance, prevents injuries or is safe in safety-sensitive roles. An absence measure cannot capture impairment, presenteeism, error rates or workplace accidents. Employers also operate under state-specific accommodation, drug-testing and federal-contract rules.
Our guide to cannabis employment and drug-testing laws explains why legal access outside work does not automatically protect on-duty use or a positive test. A state medical program can coexist with workplace restrictions, particularly in transportation, public safety and other federally regulated jobs.
Employers should therefore treat the new result as evidence that medical cannabis policy did not produce the broad absenteeism increase critics sometimes predict. It is not evidence for removing impairment policies or replacing individualized safety decisions with a single national rule.
Why the Association Could Matter
Absence is costly to workers and employers, and health-related absence can signal unmet treatment needs. A measurable reduction following medical policy changes deserves further study, especially if future research can distinguish registered patients, conditions, products and job types.
The study also adds nuance to cannabis business claims. Legalization is often sold as an economic cure, while opponents predict widespread workforce harm. The data here support neither sweeping story. One medical-policy category was associated with a modest reduction in a specific outcome, and recreational legalization showed no significant overall effect.
What Research Should Do Next
Future studies should test whether results persist in administrative payroll records, whether paid and unpaid absences move differently and whether changes are concentrated among workers with conditions eligible under state medical programs. Researchers also need better measures of actual cannabis use and workplace impairment.
Until then, the most defensible conclusion is narrow: across decades of survey data, medical cannabis decriminalization was associated with fewer health-related workplace absences. The study improves the policy evidence base, but it does not prove a treatment effect or settle the broader debate over cannabis and the workplace.